archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Glossary
    under the Therapeutic Goods Act It is the book of rules against which the Australian regulating agency therapeutic Goods Administration will audit a company to determine compliance Failure to comply may result in licence suspension Creutzfeldt Jakob disease CJD is a very rare and incurable degenerative neurological disorder brain disease that is ultimately fatal Among the types of transmissible spongiform encephalopathy it is the most common Return To Top D G Guillian Barré Syndrome GBS is an acquired immune mediated inflammatory disorder of the peripheral nervous system i e not the brain or spinal cord Return To Top H K Haemodialysis a procedure carried out on patients with kidney disease to remove certain elements from the blood by virtue of the difference in the rates of their diffusion through a semipermeable membrane Haemodialysis machines are often referred to as artificial kidney machines Haemolytic is the disruption of the integrity of red blood cells causing the release of haemoglobin Haemophilia a haemorrhagic diathesis occurring in two main forms 1 Haemophilia A classic haemophilia factor VIII deficiency an X linked disorder due to deficiency of coagulation factor VIII 2 Haemophilia B factor IX deficiency Christmas disease also X linked due to deficiency of coagulation factor IX Hepatitis C is a blood borne infectious viral disease that is caused by a virus called Hepatitis C virus HCV The infection can cause liver inflammation that is often asymptomatic but ensuing chronic hepatitis can result later in cirrhosis fibrotic scarring of the liver and liver cancer Hereditary angioedema HAE is a rare but serious genetic disorder caused by low levels or improper function of a protein called C1 inhibitor It causes swelling particularly of the face and airways and abdominal cramping Human papilloma virus HPV are a diverse group of DNA based viruses that infect the skin and mucous membranes of humans and a variety of animals More than 100 different HPV types have been characterized Some HPV types cause benign skin warts or papillomas for which the virus family is named Others can lead to the development of cervical dyskaryosis which may in turn lead to cancer of the cervix HPV infection is a necessary factor in the development of nearly all cases of cervical cancer Human papilloma virus HPV vaccine the quadrivalent Human Papillomavirus vaccine is a sterile liquid suspension prepared from the highly purified virus like particles VLPs of the recombinant major capsid L1 protein of HPV Types 6 11 16 and 18 It is indicated for the prevention of cervical vulvar and vaginal cancer precancerous or dysplastic lesions genital warts and infection caused by Human Papillomavirus HPV Types 6 11 16 and 18 Hyperimmune an immunoglobulin product having high titres of a specific antibody in the preparation Immune Thrombocytopenia ITP is a decrease in platelet numbers due to the presence of anti platelet antibodies IgG Immunisation the creation of immunity against a particular disease by stimulation of the body s immune system with a specific antigen Immunodeficiency is a deficiency in

    Original URL path: http://www.csl.com.au/glossary (2014-01-05)
    Open archived version from archive

  • Site Map
    Practice Our History Our Businesses CSL Behring CSL Plasma bioCSL Australia New Zealand United States bioCSL Immunohaematology Our Products Product Finder Complete Product List Research and Development R D Highlights Investment in R D Core Capabilities Global R D Network Product Pipeline Product Pipeline Descriptions Clinical Trials Business Development Investors Financial Reports Results Briefing Annual General Meeting Five Year Summary R D and Operational Briefings Corporate Profile Dividends Event Calendar

    Original URL path: http://www.csl.com.au/site-map (2014-01-05)
    Open archived version from archive

  • CSL Limited - Privacy Policy
    and services To carry out marketing activities and organise conferences seminars or other meetings To manage disease awareness management or other similar programs Access to health information collected about participants in clinical trials sponsored by CSL With the informed consent of participants to verify the procedures of those clinical trials Information such as names and contact details of persons who contact CSL with requests for information including through CSL s website To respond to those requests Information about applicants for employment with CSL To assess those applications for employment Information about CSL s employees and contractors relevant to their employment or contract with CSL To fulfil CSL s responsibilities as employer and contracting party How does CSL handle this information CSL is bound by the National Privacy Principles of the Privacy Act 1988 and other applicable laws governing privacy Where appropriate CSL will handle personal information relying on the related bodies corporate exemption and the employee records exemption in the Privacy Act and any other applicable exemptions in other legislation Who is the personal information disclosed to CSL will maintain control and be responsible for the security of personal information it holds As a general rule it will not provide personal information to any third parties except to regulatory bodies e g the TGA where legally obliged to do so to related companies of CSL for the same kinds of purposes as listed above to ensure continuity of service to another company if the supply of the product or service has been transferred to that company to contractors engaged to provide services in connection with the purposes mentioned above such as mail out companies agencies engaged to organise conferences and database managers who maintain and update contact information and who may contact you independently to check that information or your

    Original URL path: http://www.csl.com.au/privacy (2014-01-05)
    Open archived version from archive

  • Terms of Use
    not imply any endorsement of the linked website by CSL You link to any linked websites entirely at your own risk 5 Disclaimer The Content contained on this website is provided for general information only It should not be relied upon without obtaining specific advice from appropriate experts While CSL has used reasonable efforts to ensure that the Content contained on this website is correct and current at the time it is published CSL makes no representation and gives no warranty that the Content contained on this website is complete or accurate and takes no responsibility for any error omission or defect in such Content This website may contain forward looking statements Such statements are subject to many factors which may cause CSL s plans or results to differ from those expected These include unexpected preclinical or clinical results the need for additional research and development delays in manufacturing access to capital and funding and delays in the development of commercial relationships CSL undertakes no obligation to publicly release or update the results of any forward looking statements which may be made to reflect events or circumstances including the occurrence of unanticipated events after the date at which those statements are made 6 Limitation of Liability To the maximum extent permitted by law CSL disclaims any liability to any person arising out of any action or failure to act by that person in accessing downloading using or relying on any Content contained on this website whether caused by the negligence of CSL or otherwise Under no circumstances will CSL be liable for any indirect incidental special or consequential damages including loss of business or other profits arising in relation to the use of any Content contained in this website whether caused by the negligence of CSL or otherwise 7 Virus Warning CSL does not represent or warrant that any files obtained from or through this website are free from computer viruses or other defects Any such files are provided and may be used on the basis that the user accepts all responsibility for any loss damage or other consequence resulting directly or indirectly from the use of those files 8 Privacy When you visit this website except for information collected by CSL s internet service provider ISP CSL will not collect personally identifiable information about you unless such information is provided voluntarily by you If you decide not to provide us with personally identifiable information that may be requested you may be unable to access or receive certain information The personally identifiable information collected by CSL is strictly confidential and CSL will not reveal disclose sell distribute share or otherwise pass on to any third parties any personally identifiable information that you may have provided unless permitted by law or together with the sale or transfer of one of CSL s products or services to another person to enable continuity of supply of that product or service or CSL has your consent to do so When you visit this website

    Original URL path: http://www.csl.com.au/terms-of-use (2014-01-05)
    Open archived version from archive

  • CSL Limited Employee Section
    Outlook Web Access is available to all CSL employees enabling access to your work e mail account from anywhere there is an active Internet connection To use Outlook Web Access click on the image below Please note a secure username and password will be required A user guide is available and can be obtained from your IT helpdesk The user guide covers the basics of accessing the system its features

    Original URL path: http://www.csl.com.au/employees (2014-01-05)
    Open archived version from archive

  • General Enquiries
    Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home General Enquiries General Enquiries Required field eMail To CSL Limited Please provide your contact details Title Please select Mr Ms Mrs Mdm Dr Sir First Name Last Name Your eMail Address Suburb Town Postcode State Region Country Phone Please let

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1199979206136/page/1196562656258/FeedbackFormLong.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    REPORT 2011 2012 CSL Limited ABN 99 051 588 348 Annual Report 2011 2012 Financial calendar 2013 20 February Half year profit and interim dividend announcement 13 http www csl com au docs 494 678 csl ar 2012 0 pdf CSL Limited CSL Limited Annual Report 2010 2011 CSL Limited ABN 99 051 588 348 Annual Report 2010 2011 Annual General Meeting Wednesday 19 October 2011 at 10 00am Function Centre National http www csl com au docs 621 800 csl ar 2011 0 pdf untitled CSL LIMITED ANNUAL REPORT 2008 2009 CSL Limited ABN 99 051 588 348 Annual Report 2008 2009 YEAR IN REVIEW 1 Highlights 2 Financial Results 3 Year in Review BUSINESS FEATURES 8 CSL http www csl com au docs 470 537 csl ar 2009 pdf CSL Limited Annual Report CSL Limited Annual Report 2006 2007 CSL Limited ABN 99 051 588 348 Annual Report 2006 2007 Year in Review 1 Highlights 2 Financial Results 3 Year in Review Business Features 8 CSL http www csl com au docs 692 27 CSL AR 2007 pdf CSL Limited Our Corporate Responsibility CSL Limited Our Corporate Responsibility 2009 CSL Limited ABN 99 051 588 348 Our Corporate Responsibility 2009 Emily Bartko Emily Bartko celebrated her third birthday by having her http www csl com au docs 651 1009 CSL CSR 2009 pdf CSL LIMITED OUR CORPORATE RESPONSIBILITY CSL LIMITED OUR CORPORATE RESPONSIBILITY 2010 Contents 1 OUR ORGANISATION 04 1 1 Report of our manufacturing sites 39 7 4 CSL Plasma 44 7 5 Environmental reporting and http www csl com au 556 CSL CR Report 2010 Internet pdf CSL Limited CSL Limited our Corporate reSponSibiLity 2013 ContentS Next page CSL Limited aBN 99 051 588 348 our Corporate responsibility 2013 3 1 performance 14 3 2 Safety

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?catalog= (2014-01-05)
    Open archived version from archive

  • Press Latest Release
    grew 24 benefiting from current and past capital management initiatives http www csl com au s1 cs auhq 1187378853299 news 1255931748396 prdetail htm 1255931748396 Wed 14 Aug 2013 00 00 00 0500 CSL announces Changes to the Board CSL Limited ASX CSL today announced that Ms Marie McDonald has been appointed a Director effective from 14 August 2013 The Company also announced that Mr Ian Renard AM has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company s Annual General Meeting on 16 October 2013 http www csl com au s1 cs auhq 1187378853299 news 1255931748562 prdetail htm 1255931748562 Thu 08 Aug 2013 00 00 00 0500 Notice of Investor Analyst Briefing Result FY2013 CSL Limited ASX CSL CSL Limited rsquo s 2013 full year results will be announced on Wednesday 14 August 2013 nbsp http www csl com au s1 cs auhq 1187378853299 news 1255931709204 prdetail htm 1255931709204 Thu 04 Jul 2013 01 00 00 0500 CSL progresses new bleeding disorder therapies CSL Limited has this week presented promising results from a number of clinical studies involving a new group of therapies for the treatment of haemophilia http www csl com au s1 cs auhq 1187378853299 news 1255931560067 prdetail htm 1255931560067 Fri 28 Jun 2013 00 00 00 0500 Terms of Departure of Managing Director and CEO CSL Limited ASX CSL has previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from 1 July 2013 http www csl com au s1 cs auhq 1187378853299 news 1255931529049 prdetail htm 1255931529049 Wed 19 Jun 2013 00 00 00 0500 CSL Limited Changes to Segment Reporting In February 2013 the Company announced the completion of the reorganisation of its Australian Operations which took effect from 1 January 2013 and advised that financial reporting reflecting this new organisational structure would be shown in the segment reporting commencing with the FY2013 results http www csl com au s1 cs auhq 1187378853299 news 1255931478572 prdetail htm 1255931478572 Tue 30 Apr 2013 02 00 00 0500 bioCSL Goes Back into Influenza Vaccine Production for Australia bioCSL announced today that it has recently restarted production of influenza vaccine for the Australian market in response to higher than expected demand this season http www csl com au s1 cs auhq 1187378853299 news 1255931255978 prdetail htm 1255931255978 Mon 29 Apr 2013 02 00 00 0500 bioCSL Awarded Major Vaccine Distribution Contracts bioCSL has been selected by New South Wales Health NSW Health and the Western Australian Department of Health WA DoH to provide storage and distribution services for government funded vaccine programs The contracts awarded after separate tender processes have a combined value of 6 8 million http www csl com au s1 cs auhq 1187378853299 news 1255931252667 prdetail htm 1255931252667 Fri 05 Apr 2013 00 00 00 0500 CSL Half Year Report 2012 13 bioCSL has been selected by New South Wales Health NSW Health and the

    Original URL path: http://www.csl.com.au/s1/cs?lang=AU&site=HQ&pagename=HQ/Web_News_P/RSS_PressReleases&cat=1145993773124&p=1187378853299 (2014-01-05)
    Open archived version from archive